Pharmaceutical development of a parenteral lyophilised dosage form for the novel anticancer agent C1311

PDA Journal of Pharmaceutical Science and Technology

Volumn 59, Issue 5, 2005, Pages 285-297

  Den Brok, Monique W J ^a   Nuijen, Bastiaan ^a   Kettenes Van Den Bosch, J Jantina ^b   Van Steenbergen, M J ^b   Buluran, Josie N ^c   Harvey, Michael D ^c   Grieshaber, Charles K ^d   Beijnen, Jos H ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^d Xanthus Life Sciences Inc   (United States)

Author keywords

Analytical characterisation; C1311; Formulation; Lyophilisation; Structural characterisation

Indexed keywords

ACRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; BUFFER; BULKING AGENT; EXCIPIENT; IMIDACRINE; IMIDAZOACRIDINONE; IMIDAZOLE DERIVATIVE; KETONE; MANNITOL; NEW DRUG; SODIUM DIHYDROGEN PHOSPHATE; SUCROSE; TROMETAMOL; UNCLASSIFIED DRUG;

ARTICLE; CHROMATOGRAPHY; COLON TUMOR; CYTOTOXICITY; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STERILITY; DRUG STORAGE; DRUG STRUCTURE; FREEZE DRYING; IN VITRO STUDY; IN VIVO STUDY; SPECTROMETRY; X RAY DIFFRACTION;

AGED, 80 AND OVER; AMINOACRIDINES; ANTINEOPLASTIC AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLINICAL TRIALS, PHASE I; DRUG COMPOUNDING; DRUG CONTAMINATION; DRUG STABILITY; DRUG STORAGE; FREEZE DRYING; HUMANS; INFUSIONS, PARENTERAL; PHARMACEUTICAL SOLUTIONS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 27744566713     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. 285-297 1. Cholody, W. M.; Martelli, S.; Paradziej-Lukowicz, J.; Konopa, J. 5-[(Aminoalkyl)amino]imidazo [4,5,1-de]acridin-6-ones as a novel class of antineoplastic agents. Synthesis and biological activity. J. Med. Chem. 1990, 33, 49.
2. Showalter, H. D.; Fry, D. W.; Leopold, W. R.; Lown, J. W.; Plambeck, J. A.; Reszka, K. Design, biochemical pharmacology, electrochemistry and tumour biology of anti-tumour anthrapyrazoles. Anti-Cancer Drug Des. 1986, 1, 73.
3. Burger, A. M.; Double, J. A.; Konopa, J.; Bibby, M. C. Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer. Br. J. Cancer 1996, 74, 1369.
4. Dziegielewski, J.; Slusarski, B.; Konitz, A.; Skladanowski, A.; Konopa, J. Intercalation of imidazoacridinones to DNA and its relevance to cytotoxic and antitumor activity. Biochem. Pharmacol. 2002, 63, 1653.
5. Skladanowski, A.; Plisov, S. Y.; Konopa, J.; Larsen, A. K. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors. Mol. Pharmacol. 1996, 49, 772.
6. Cholody, W. M.; Martelli, S.; Konopa, J. Chromophore-modified antineoplastic imidazoacridinones. Synthesis and activity against murine leukemias. J. Med. Chem. 1992, 35, 378.
7. Augustin, E.; Wheatley, D. N.; Lamb, J.; Konopa, J. Imidazoacridinones arrest cell-cycle progression in the G2 phase of L1210 cells. Cancer Chemother. Pharmacol. 1996, 38, 39.
8. Alami, N.; Paterson, J.; Belanger, S.; Grieshaber, C. K.; Leyland-Jones, B. In vitro and in vivo activity of C1311 and paclitaxel in three cancer tumor models [Abstract no. 4632]. Proceedings of the American Association for Cancer Research 95th Annual Meeting, Orlando, FL, March 27-31, 2004.
9. Alami, N.; Paterson, J.; Belanger, S.; Juste, S.; Grieshaber, C. K.; Leyland-Jones, B. Comparative in vitro analysis of C1311 activity in a panel of colorectal cell lines against standard colon cancer chemotherapies [Abstract no. 2062]. Proceedings of the American Association for Cancer Research 95th Annual Meeting, Orlando, FL, March 27-31, 2004.
10. Alami, N.; Paterson, J.; Belanger, S.; Grieshaber, C. K.; Leyland-Jones, B. Evaluation of in vitro hematotoxicity of C1311, mitoxantrone and oxaliplatin to CFU-GM committed neutrophil-monocyte progenitors from human and rat [Abstract no. 2110]. Proceedings of the American Association for Cancer Research 95th Annual Meeting, Orlando, FL, March 27-31, 2004.
11. European Pharmacopoeia, 4th ed., Council of Europe: Strasbourg, 2002.
12. United States Pharmacopoeia, 24th ed., United States Pharmacopoeial Convention Inc.: Rockville, MD, 2000.
13. Den Brok, M. W. J.; Nuijen, B.; Hillebrand, M. J. X.; Grieshaber, C. K.; Harvey, M. D.; Beijnen, J. H. Development and validation of an LC-UV method for the quantification and purity determination of the novel anticancer agent C1311 and its pharmaceutical dosage form. In press: J. Pharm. Biomedical. Anal. 2005.
14. European Commission. Commision Directive 200/94/EC: Medicinal Products for Human and Veterinary Use-Good Manufacturing Practices; available at http://pharmacos.eudra.org/F2/eudralex/vol-4/home.htm, 2003.
15. Kim, A. I.; Akers, M. J.; Nail, S. L. The physical state of mannitol after freeze-drying: effects of mannitol concentration, freezing rate, and a non-crystallizing cosolute. J. Pharm. Sci. 1998, 87, 931.
16. Wang, W. Lyophilization and development of solid protein pharmaceuticals. Int. J. Pharm. 2000, 203, 1.
17. Shalaev, E. Y.; Lu, Q.; Shalaeva, M.; Zografi, G. Acid-catalyzed inversion of sucrose in the amorphous state at very low levels of residual water. Pharm. Res. 2000, 17, 366.
18. Izutsu, K.; Yoshioka, S.; Terao, T. Effect of mannitol crystallinity on the stabilization of enzymes during freeze-drying. Chem. Pharm. Bull. (Tokyo) 1994, 42, 5.
19. Cavatur, R. K.; Vemuri, N. M.; Pyne, A.; Chrzan, Z.; Toledo-Velasquez, D.; Suryanarayanan, R. Crystallization behavior of mannitol in frozen aqueous solutions. Pharm. Res. 2002, 19, 894.
20. Izutsu, K.; Yoshioka, S.; Terao, T. Decreased protein-stabilizing effects of cryoprotectants due to crystallization. Pharm. Res. 1993, 10, 1232.
21. Cakala, M.; Mazerska, Z.; Donten, M.; Stojek, Z. Electroanalytical and acid-base properties of imidazoacridinone, an antitumor drug (C-1311). Anal. Chim. Acta 1999, 379, 209.
22. Stafford, J. Calculating the risk of batch failure in the manufacture of drug products. Drug Dev. Ind. Pharm. 1999, 25, 1083.
23. ICH Steering Committee. ICH QlA (R2) Stability Testing of New Drugs and Products. European Agency for the Evaluation of Medicinal Products, International Commission on Harmonisation: London (CPMP/ICH/2736/99), 2003. Available at: http://www.ich.org
24. Wang, Z.; Frankel, B. A.; Lambert, W. J. Determination of moisture in rubber stoppers: effect of Karl Fischer oven temperatures. PDA J. Pharm. Sci. Technol. 2001, 55, 162.
25. Templeton, A. C.; Placek, J.; Xu, H.; Mahajan, R.; Hunke, W. A.; Reed, R. A. Determination of the moisture content of bromobutyl rubber stoppers as a function of processing: implications for the stability of lyophilized products. PDA J. Pharm. Sci. Technol. 2003, 57, 75.